Open AccessPrevention of Thromboembolic Complications afterSurgical Treatment for Lower Extremity BoneFractures: Experience in Rivaroxaban Use in ClinicalPractice
Author(s) -
О.А. Каплунов,
S. N. Biryukov,
E. Yu. Nekrasov
Publication year - 2016
Publication title -
vestnik travmatologii i ortopedii imeni n.n. priorova
Language(s) - English
Resource type - Journals
eISSN - 2658-6738
pISSN - 0869-8678
DOI - 10.17816/vto201623257-61
Subject(s) - rivaroxaban , medicine , perioperative , deep vein , thrombosis , surgery , blood loss , anesthesia , atrial fibrillation , warfarin
Comparative evaluation of rivaroxaban (main group, n=37) and enoxaparin (control group, n=29) safety in thromboprophylaxis at closed lower extremity bone fractures treatment was performed. All patients were operated on at terms from 8 to 12 day after injury using external fixation devices. The volume of intra- and perioperative blood loss in the groups did not differ significantly ( p >0.05). The rate of symptomatic thromboembolic complications, i.e. calf deep vein thrombosis confirmed by clinical data, was significantly lower in patients from the main group (2.7%) as compared to the control group (6.8%; p